
Allarity Therapeutics (ALLR) Stock Forecast & Price Target
Allarity Therapeutics (ALLR) Analyst Ratings
Bulls say
Allarity Therapeutics is a clinical-stage, precision medicine pharmaceutical company with a novel Drug Response Predictor (DRP) platform that aims to improve patient selection for their lead program Stenoparib, currently in Phase 2 trials for ovarian and small cell lung cancer. Stenoparib has shown promising results in trials, with some patients still receiving benefits after 29 months on therapy and a median overall survival of 25 months. With a large market potential for ovarian cancer and the growing PARP inhibitors market, coupled with a positive balance sheet and recent Q3 results, Allarity presents as a high-risk, high-reward opportunity for investors.
Bears say
Allarity Therapeutics is currently trading at an attractive valuation, with a BUY rating and a raised 12-month price target of $9.75 based on a NPV analysis. While there are risks involved, such as balance sheet and liquidity risks, the company's innovative DRP platform and its main drug candidate, Stenoparib, show potential for personalized and precision medicine in the treatment of ovarian cancer, with recent data showing promising results and a large market potential. The company has a strong balance sheet, with enough cash to support its operations until at least late 2026.
This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Allarity Therapeutics (ALLR) Analyst Forecast & Price Prediction
Start investing in Allarity Therapeutics (ALLR)
Order type
Buy in
Order amount
Est. shares
0 shares